Al‐Alaiyan 1996.
Methods | Blinding of randomisation: yes Blinding of intervention: can't tell but probably impossible Complete follow‐up: yes Blinding of outcome measurement: can't tell | |
Participants | Term and premature infants, >36 weeks GA, >24 hours of age. Qualifying SBR 170‐300 (direct SBR <25). Haemolysis excluded. Fibreoptic n=15, conventional n=15. | |
Interventions | Fibreoptic: BiliBlanket at 22.34 microwatts/cm2/nm (measured). Conventional: Air‐Shields (white) at 11.6 microwatts/cm2/nm (measured). | |
Outcomes | Duration of phototherapy (no SBR level specified for cessation of phototherapy therefore not included). Absolute SBR at beginning and end of treatment. | |
Notes | Data complete | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Low risk | A ‐ Adequate |